SG173997A1 - Human endogenous retrovirus polypeptide compositions and methods of use thereof - Google Patents

Human endogenous retrovirus polypeptide compositions and methods of use thereof Download PDF

Info

Publication number
SG173997A1
SG173997A1 SG2011052784A SG2011052784A SG173997A1 SG 173997 A1 SG173997 A1 SG 173997A1 SG 2011052784 A SG2011052784 A SG 2011052784A SG 2011052784 A SG2011052784 A SG 2011052784A SG 173997 A1 SG173997 A1 SG 173997A1
Authority
SG
Singapore
Prior art keywords
herv
polypeptide
cells
leu
cell
Prior art date
Application number
SG2011052784A
Other languages
English (en)
Inventor
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Mario Ostrowski
R Bradley Jones
Ashish Agrawal
Jack Lenz
Seth Rakoff-Nahoum
Frederick M Hecht
Original Assignee
Univ California
David Gladstone Inst
Einstein Coll Med
Mario Ostrowski
R Bradley Jones
Rakoff Nahoum Seth Ferguson Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, David Gladstone Inst, Einstein Coll Med, Mario Ostrowski, R Bradley Jones, Rakoff Nahoum Seth Ferguson Singapore Pte Ltd filed Critical Univ California
Publication of SG173997A1 publication Critical patent/SG173997A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG2011052784A 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof SG173997A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21

Publications (1)

Publication Number Publication Date
SG173997A1 true SG173997A1 (en) 2011-09-29

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011052784A SG173997A1 (en) 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof

Country Status (15)

Country Link
US (2) US20080171061A1 (https=)
EP (1) EP2046380A4 (https=)
JP (1) JP2009544614A (https=)
KR (1) KR20090060410A (https=)
CN (1) CN101557823A (https=)
AU (1) AU2007275693A1 (https=)
BR (1) BRPI0714714A2 (https=)
CA (1) CA2658393A1 (https=)
IL (1) IL196516A0 (https=)
MX (1) MX2009000659A (https=)
NO (1) NO20090818L (https=)
RU (1) RU2009106089A (https=)
SG (1) SG173997A1 (https=)
WO (1) WO2008011120A2 (https=)
ZA (1) ZA200900379B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
US8323659B2 (en) * 2008-09-18 2012-12-04 Keio University Method for diagnosing and/or treating tumor
US20110250218A1 (en) * 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
EP2519539A4 (en) * 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102593047B1 (ko) 2012-01-26 2023-10-24 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
EP2970985A1 (en) 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US11779603B2 (en) 2016-06-30 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HERV-E reactive T cell receptors and methods of use
CA3033262A1 (en) * 2016-08-23 2018-03-01 Aimvion A/S Novel immunostimulating peptides
CN110121336A (zh) 2017-01-05 2019-08-13 弗莱德哈钦森癌症研究中心 改善疫苗功效的系统和方法
CA3058807A1 (en) * 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
DK3676285T3 (da) 2017-09-01 2026-01-19 Inprother Aps Vaccine til anvendelse i profylakse og/eller behandling af en sygdom
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
KR20250099256A (ko) 2018-01-18 2025-07-01 프레드 허친슨 캔서 센터 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
WO2020049169A1 (en) * 2018-09-06 2020-03-12 Centre Léon-Bérard Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3189601A1 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
WO2024108001A2 (en) * 2022-11-16 2024-05-23 The General Hospital Corporation Minimal human-derived virus-like particles and methods of use thereof for delivery of biomolecules
US20260035415A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US20030162263A1 (en) * 2001-09-06 2003-08-28 Marc Dupuis Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
US20070037147A1 (en) * 2001-12-07 2007-02-15 Pablo Garcia Endogenous retrovirus polypeptides linked to oncogenic transformation
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
WO2011077093A1 (en) * 2009-12-22 2011-06-30 Aarhus Universitet Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
US20130323279A1 (en) 2013-12-05
ZA200900379B (en) 2010-08-25
EP2046380A2 (en) 2009-04-15
WO2008011120A2 (en) 2008-01-24
NO20090818L (no) 2009-04-17
RU2009106089A (ru) 2010-08-27
US20080171061A1 (en) 2008-07-17
JP2009544614A (ja) 2009-12-17
BRPI0714714A2 (pt) 2013-04-09
AU2007275693A1 (en) 2008-01-24
CN101557823A (zh) 2009-10-14
WO2008011120A3 (en) 2008-11-06
CA2658393A1 (en) 2008-01-24
EP2046380A4 (en) 2013-05-01
IL196516A0 (en) 2011-08-01
MX2009000659A (es) 2009-06-08
KR20090060410A (ko) 2009-06-12

Similar Documents

Publication Publication Date Title
SG173997A1 (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
US20110046042A1 (en) Long Interspersed Nuclear Element Polypeptide Compositions and Methods of Use Thereof
US11660335B2 (en) Vaccines against coronavirus and methods of use
US8043623B2 (en) Immunogenic peptides for the treatment of prostate and breast cancer
SK4022003A3 (en) HIV peptides, antigens, vaccine compositions, an immunoassay kit and method of detecting antibodies induced by HIV
SK12402001A3 (sk) Peptidy HIV, antigény, zloženie vakcín, súprava na imunologickú skúšku a spôsob detekcie protilátok vyvolaných HIV
EP1309860B1 (fr) Procede de criblage de peptides utilisables en immunotherapie
JP2015500854A (ja) エンベロープウイルスにより引き起こされる疾病を治療するための方法および組成物
IT202000009688A1 (it) Proteine di fusione di ancoraggio a esosomi
US20230310585A1 (en) Vaccine for viral pathogens
US9572873B2 (en) Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins
US9486518B2 (en) Membrane proximal region of HIV GP41 anchored to the lipid layer of a virus-like particle vaccine
WO2014022475A2 (en) Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
US20220370598A1 (en) Vaccines Against Coronavirus and Methods of Use
WO2005005465A2 (en) Methods and compositions to enhance immune responses via recall antigens
HK1135023A (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
US20080267989A1 (en) Hiv Gp-41-Membrane Proximal Region Arrayed On Hepatitis B Surface Antigen Particles as Novel Antigens
Berzofsky Human Immunodeficiency Virus: Structural Features of T-Cell
WO2022125610A1 (en) Perforin inhibitors and uses thereof
Maksaereekul et al. Cloning and Sequencing of Feline CD107a
US20060122368A1 (en) Antigen delivery platform